Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study

A bibliometric analysis of acute myocardial infarction in women from 2000 to 2022

Background

Plenty of publications had been written in the last several decades on acute myocardial infarction (AMI) in women. However, there are few bibliometric analyses in such field. In order to solve this problem, we attempted to examine the knowledge structure and development of research about AMI in women based on analysis of related publications.

Method

The Web of Science Core Collection was used to extract all publications regarding AMI in women, ranging from January 2000 to August 2022. Bibliometric analysis was performed using VOSviewer, Cite Space, and an online bibliometric analysis platform.

Results

A total of 14,853 publications related to AMI in women were identified from 2000 to 2022. Over the past 20 years, the United States had published the most articles in international research and participated in international cooperation the most frequently. The primary research institutions were Harvard University and University of Toronto. Circulation was the most cited journal and had an incontrovertible academic impact. 67,848 authors were identified, among which Harlan M Krumholz had the most significant number of articles and Thygesen K was co-cited most often. And the most common keywords included risk factors, disease, prognosis, mortality, criteria and algorithm.

Conclusion

The research hotspots and trends of AMI in women were identified and explored using bibliometric and visual methods. Researches about AMI in women are flourishing. Criteria and algorithms might be the focus of research in the near future, which deserved great attentions.

Persistence with Antiplatelet and Risk of Major Adverse Cardiac and Cerebrovascular Events in Acute Coronary Syndrome Patients after Percutaneous Coronary Intervention in Indonesia: A Retrospective Cohort Study

BACKGROUND: Acute coronary syndrome (ACS) is a life-threatening condition that carries high risk of recurrent cardiovascular events and death. Persistence with treatment is known to reduce morbidity and mortality in patients with ACS. AIM: This study focuses on ACS patients undergoing their first percutaneous coronary intervention (PCI) to investigate the association between persistence with antiplatelet therapy and clinical outcomes. MATERIALS AND METHODS: A retrospective cohort study with 2 years of follow-up was conducted with 367 patients recruited. Patients were deemed as having persistence with antiplatelet therapy (WHO ATC code: B0A1C), if the gap between prescriptions was ≤30 days. The clinical outcomes were defined as a composite of major adverse cardiac event (MACE), major adverse cardiovascular and cerebrovascular events (MACCE), myocardial infarction, recurrent PCI, stroke, all-cause death, cardiovascular death, and hospitalization. RESULTS: Cumulative persistence with antiplatelet showed that 72.3% of all ACS patients were still taking antiplatelet 1 year after PCI. Persistence to treatment with antiplatelet therapy can be used as a predictor of MACE or MACCE, because it was associated with recurrent PCI (RR 3.09, 95% CI = 1.18−8.05). History of cardiovascular disease in non-persistence patients was associated with increased risk of MACE (RR 4.90 95% CI = 1.37−17.48) and MACCE (RR 3.67 95% CI = 1.12−11.98) events. CONCLUSION: After PCI, not all ACS patients continued taking their drug exactly as prescribed. Our study indicates that among ACS patients who underwent their first PCI, non-persistence with antiplatelet therapy might lead to worse clinical outcomes. This data will help promote secondary prevention among ACS patients after PCI.

Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper

INTRODUCTION

Long-term follow-up after an acute coronary syndrome (ACS) presents a crucial challenge due to the high residual cardiovascular risk and the potential for major bleeding events. Although several treatment strategies are available, this article focuses on patients who have undergone percutaneous coronary intervention (PCI) for ACS, which is a frequent clinical situation. This position paper aims to support physicians in daily practice to improve the management of ACS patients.

MATERIAL AND METHODS

A group of recognized international and French experts in the field provides an overview of current evidence-based recommendations - supplemented by expert opinion where such evidence is lacking - and a practical guide for the management of patients with ACS after hospital discharge.

RESULTS

The International Collaborative Group underlines the need of a shared collaborative approach, and a care plan individualized to the patient's risk profile for both ischaemia and bleeding. Each follow-up appointment should be viewed as an opportunity to optimize the personalized approach, to reduce adverse clinical outcomes and improve quality of life. As risks - both ischaemic and haemorrhagic - evolve over time, the risk-benefit balance should be assessed in an ongoing dynamic process to ensure that patients are given the most suitable treatment at each time point.

CONCLUSIONS

This Expert Opinion aims to help clinicians with a practical guide underlying the proven strategies and the remaining gaps of evidence to optimize the management of coronary patients.

Application of Artificial Intelligence in Acute Coronary Syndrome: A Brief Literature Review

Artificial intelligence (AI) is defined as a set of algorithms and intelligence to try to imitate human intelligence. Machine learning is one of them, and deep learning is one of those machine learning techniques. The application of AI in healthcare systems including hospitals and clinics has many possible advantages and future prospects. Applications of AI in cardiovascular medicine are machine learning techniques for diagnostic procedures including imaging modalities and biomarkers and predictive analytics for personalized therapies and improved outcomes. In cardiovascular medicine, AI-based systems have found new applications in risk prediction for cardiovascular diseases, in cardiovascular imaging, in predicting outcomes after revascularization procedures, and in newer drug targets. AI such as machine learning has partially resolved and provided possible solutions to unmet requirements in interventional cardiology. Predicting economically vital endpoints, predictive models with a wide range of health factors including comorbidities, socioeconomic factors, and angiographic factors comprising of the size of stents, the volume of contrast agent which was infused during angiography, stent malposition, and so on have been possible owing to machine learning and AI. Nowadays, machine learning techniques might possibly help in the identification of patients at risk, with higher morbidity and mortality following acute coronary syndrome (ACS). AI through machine learning has shown several potential benefits in patients with ACS. From diagnosis to treatment effects to predicting adverse events and mortality in patients with ACS, machine learning should find an essential place in clinical medicine and in interventional cardiology for the treatment and management of patients with ACS. This paper is a review of the literature which will focus on the application of AI in ACS.

Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study

OBJECTIVES

The objective of this study is to examine the temporal trend of antiplatelet prescribing pattern during index hospitalisation discharge in Hong Kong (HK) acute coronary syndrome (ACS) population.

DESIGN

The study is a retrospective observational cohort study.

SETTING

The study retrieved data from electronic health record from Hospital Authority (HA), HK.

PARTICIPANTS

The study included patients aged 18 years old or above, who were admitted to seven institutions under HA with diagnosis of ACS during 2008-2017.

PRIMARY AND SECONDARY OUTCOME MEASURES

The primary outcome was the frequency of antiplatelet therapy prescription at the point of index hospitalisation discharge each year during 2008-2017. Association between demographics, baseline comorbidities, procedures and antiplatelet prescription were examined as secondary outcome using multivariate logistic regression model, with commonly used antiplatelet groups selected for comparison.

RESULTS

Among the included 14 716 patients, 5888 (40.0%) discharged with aspirin alone, 6888 (46.8%) discharged with dual antiplatelet therapy (DAPT) with clopidogrel, and 973 (6.6%) discharged with DAPT with prasugrel/ticagrelor. Prescribing rate of aspirin alone decreased substantially from 56.8% in 2008 to 27.5% in 2017. Utilisation of DAPT with clopidogrel increased from 33.7% in 2008 to 52.7% in 2017. Use of DAPT with prasugrel/ticagrelor increased from 0.3% in 2010 to 15.3% in 2017. Compared with those prescribed with DAPT with clopidogrel, male patients (adjusted OR (aOR) 1.34, 95% CI 1.09 to 1.65), patients with non-ST-elevation myocardial infarction (aOR 2.50, 1.98 to 3.16) or ST-elevation myocardial infarction (aOR 3.26, 2.59 to 4.09), use of glycoprotein IIb/IIIa (aOR 3.03, 2.48 to 3.68) or undergoing percutaneous coronary intervention (aOR 3.85, 3.24 to 4.58) or coronary artery bypass graft (aOR 6.52, 4.63 to 9.18) during index hospitalisation, concurrent use of histamine-2 receptor antagonists (aOR 1.35, 1.10 to 1.65) or proton pump inhibitors (aOR 3.57, 2.93 to 4.36) during index hospitalisation discharge were more likely to be prescribed with DAPT with prasugrel/ticagrelor. Patients with older age (aOR 0.97, 0.96 to 0.97), diabetes (aOR 0.68, 0.52 to 0.88), chronic kidney disease (aOR 0.43, 0.22 to 0.85) or concurrent use of oral anticoagulant (aOR 0.16, 0.07 to 0.42) were more likely to received DAPT with clopidogrel.

CONCLUSIONS

Use of DAPT with prasugrel/ticagrelor was suboptimal yet improving during 2008-2017 in HK patients with ACS. Considering DAPT, predictors for clopidogrel prescription, compared with prasugrel/ticagrelor, were consistent with identified risk factors of bleeding.

Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China

OBJECTIVES

To investigate the initiation and persistence of antiplatelet agents and the associated factors for patients with acute coronary syndromes (ACS) in Tianjin, China.

METHODS

Data were obtained from Tianjin Urban Employee Basic Medical Insurance database (2011-2015). Adult patients who were discharged alive after the first ACS-related hospitalization (index hospitalization) between January 2012 and December 2014 were included. Patients who initiated with antiplatelet therapy, including aspirin monotherapy, clopidogrel monotherapy, or dual antiplatelet with aspirin and clopidogrel at discharge or within the initial 30-day follow-up after discharge were further identified. Patients with no gaps of ≥30 days in antiplatelet therapy were deemed persistent. The logistic model and Cox model were used to explore the associated factors of initiation and persistence with antiplatelet agents, respectively.

RESULTS

In total, 21,450 patients (64.6±10.7 years; 46.0% female) were included. Only 70.3% (N=15,071) of them initiated with antiplatelet agents within the initial 30-day follow-up; 85.0% (N=12,809) of the initial users discontinued their antiplatelet therapy, and the average time to discontinuation was 117.4±119.7 days. The patients who had prior antiplatelet agents utilization (Odds ratio [95% CI]=1.93 [1.78-2.09]; hazard ratio [95% CI]=0.78 [0.74-0.81]), received percutaneous coronary intervention (PCI) during the baseline period (OR=1.47 [1.26-1.73]; HR=0.91 [0.84-0.97]) or index hospitalization (OR=22.40 [18.63-26.92]; HR=0.51 [0.49-0.53]) were more likely to initiate and persist with antiplatelet agents, while the female (OR=0.75 [0.70-0.81]; HR=1.22 [1.88-1.27]) patients were less likely to initiate and persist with antiplatelet agents.

CONCLUSION

The initiation and persistence with antiplatelet agents are poor among the ACS patients in Tianjin. Females are associated with poorer initiation and persistence, while prior antiplatelet agents use and receiving PCI during baseline period or index hospitalization are associated with better initial use and better persistence.